BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


SEARCH JOBS










 Company News
Boehringer Ingelheim Corporation Initiates Global Phase 3 Study Investigating Nintedanib In Patients With Colorectal Cancer 10/21/2014 7:17:00 AM
Boehringer Ingelheim Corporation Wins FDA Approval For Lung Disease Drug Ofev 10/15/2014 3:14:19 PM
Boehringer Ingelheim Corporation And Americares Partner To Expand Product Donations Program Globally 10/15/2014 10:49:17 AM
Boehringer Ingelheim Corporation Release: New COPD Maintenance Treatment Striverdi® Respimat® (olodaterol) Inhalation Spray Now Available in U.S. Pharmacies 10/8/2014 8:15:53 AM
Boehringer Ingelheim Corporation To Create 100 New Jobs With $125 Million+ Site Expansion 10/1/2014 6:49:45 AM
Boehringer Ingelheim Corporation's Afatinib Meets Primary Endpoint In Phase 3 Study Of Head And Neck Cancer 9/29/2014 7:15:13 AM
Boehringer Ingelheim Corporation Release: Nintedanib* Receives Positive CHMP Opinion For Second-Line Treatment Of Patients With Adenocarcinoma Of The Lung 9/26/2014 8:17:23 AM
Boehringer Ingelheim Corporation Plans To Cut Up To 600 Jobs 9/23/2014 6:42:19 AM
Boehringer Ingelheim Corporation Will Pay Up To $600 Million For CureVac GmbH Lung Cancer Vaccine 9/18/2014 6:21:48 AM
Boehringer Ingelheim Corporation Release: Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Shows Sustained Reduction In Blood Glucose In Phase 3 Study 9/16/2014 9:22:37 AM
12345678910...